Regulatory approval

Published by the Health Canada.

Health Canada approved selpercatinib as monotherapy for the treatment of RET fusion-positive differentiated thyroid carcinoma in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib.

This is written in the approval document as:

RETEVMO (selpercatinib) is indicated as monotherapy for the treatment of RET fusion-positive differentiated thyroid carcinoma in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib.

Citation

Loxo Oncology Inc. Retevmo (selpercatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078253.PDF. Revised January 2025. Accessed June 2025.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	v::RET	Papillary Thyroid Cancer	Selpercatinib